WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Resources > Whitepapers > Anti-Microbial Resistance and the search for New Antibiotics
I'm For Real
Enter your details once to access all our information and resources
Biocard is a full service contract research organization (CRO) and a full cycle logistics company.
whitePaper | December 14, 2022
When the regulatory hammer came down on pharmaceutical and life sciences (PLS) companies in the 2010s, it introduced new complexities for these businesses.
whitePaper | August 8, 2022
Biopharma R&D professionals generally admit that the current "high-cost, high-risk" development model is unsustainable. Despite technological.
whitePaper | May 24, 2022
Our proprietary nanoforming technologies and services span the full range of drug development from small-molecule nanoparticles to large-molecule biologics.
whitePaper | September 15, 2022
The sheer size of the pharmaceutical industry makes it important for all stakeholders to stay up to date with pharmaceutical industry trends.
whitePaper | July 13, 2023
Most medicines in development today target diseases affecting large sections of the global population. But now we are slowly beginning to see a rise in the interest of developing ”orphan drugs,” or pharmaceutical agents intended to treat rare diseases.
whitePaper | October 13, 2022
In our previous edition of the Clinical Trials Roundup1, we explored the acute disruptions that the COVID-19 pandemic brought to the clinical trials landscape in 2020.
Conference
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE